Ultime notizie per CalciMedica (NASDAQ:CALC) Azioni

CALCIMEDICA INC

CalciMedica

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

CalciMedica Inc

Calcitech Ltd

Calcol Inc

Keefe, Bruyette &amp; Woods analyst Tommy McJoynt maintains Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) with a Outperform and lowers the price target from $230 to $224.

News

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Outperform on Assurant, Lowers Price Target to $224

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Ryan Specialty Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) with a Outperform and lowers the price target from $76 to $75.

RYAN

Keefe, Bruyette & Woods Maintains Outperform on Ryan Specialty Hldgs, Lowers Price Target to $75

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains The Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) with a Market Perform and lowers the price target from $179 to $171.

Keefe, Bruyette & Woods Maintains Market Perform on The Hanover Insurance Gr, Lowers Price Target to $171

Jefferies analyst Stephanie Moore maintains ArcBest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCB#NASDAQ">ARCB</a>) with a Buy and lowers the price target from $120 to $95.

ARCB

Jefferies Maintains Buy on ArcBest, Lowers Price Target to $95

Sirius XM Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) has a stable business model that is based on recurring subscription revenues, which makes it a "recession-resistant port in the tariff storm," according to Seaport Research Partners
The Sirius XM Holdings Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58f614b60bd9910001a77adf/david-joyce">Analyst David Joyce</a> upgraded the rating from Neutral to Buy, while keeping the price target unchanged at $27.
The Sirius XM Holdings Thesis: The company's business model makes subscribers "sticky" and its recurring subscription revenues are 100% US, Joyce said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Sirius XM Holdings is likely to generate around 13% growth in free cash flows this year and the next, he added.
"We believe any tariff impacts on car sales would have a de minimis impact on 2025 operations (as it would generally take at least a quarter for a gross addition to turn into revenue post-conversion)," the analyst wrote.
The company faces a soft ad environment, with ad budgets continuing to shift to digital video. However, only around 20% of its revenue has exposed to advertising, Joyce stated.
Given its healthy free cash flow growth, Sirius XM Holdings is likely to continue offering a "telco-like 5% dividend yield," he added.
SIRI Price Action: Shares of Sirius XM Holdings had risen by 3.62% to $20.04 at the time of publication on Wednesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44541934/sirius-xm-bets-on-ev-growth-cheaper-plans-to-boost-subscribers-analyst">SiriusXM Bearish Analyst Highlights Key Near-Term Challenges</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Upgrades

Movers

Trading Ideas

SIRI

Sirius XM Is 'Recession-Resistant Port In Tariff Storm': Analyst

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Market Perform and lowers the price target from $64 to $62.

Keefe, Bruyette & Woods Maintains Market Perform on WR Berkley, Lowers Price Target to $62

With the stock market sliding and fear running high, <a href="https://www.benzinga.com/personal-finance/25/02/43769106/2-million-is-pennies-suze-orman-says-if-you-think-youll-be-able-to-survive-on-80000-a-year-in-retirement-ive-got-a-bridge-to-sell-you">Suze Orman</a> jumped in this week with a reminder that's equal parts firm and familiar: don't let panic do the decision-making.
"We are looking at another down day for the markets," she <a href="https://www.facebook.com/share/18hD21yLy2/?mibextid=wwXIfr">wrote in a Facebook post</a> over the weekend. "Why? Well, China has retaliated, and that's got investors on edge." Between the global headlines and market volatility, she says it's starting to look—and feel—a lot like 2022. "Volatile. Emotional. Uncertain."
But here's where she draws the line: "When sentiment is this fearful, it is not the time to sell."
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
Her advice is clear: keep your head, and keep your money where it belongs—if you can afford to. "Money you have in the market should have been money you did not need for at least five years," she said. "Let this play out."
That's not a green light to throw everything at the market, either. If you're dollar-cost averaging, she says, go small. "Do it with seriously tiny amounts. This is not the time to be aggressive."
One of her strongest messages was this: <a href="https://www.benzinga.com/personal-finance/25/03/44316684/warren-buffett-said-bad-news-is-an-investors-best-friend-and-if-youre-not-ready-for-stocks-to-drop-50-you-shouldnt-be-investing">don't stop investing just because the market is down</a>. "If you are contributing to a retirement account, do not stop. Stay the course. Keep investing steadily. That <a href="https://www.benzinga.com/markets/25/04/44657155/buffetts-warning-as-stocks-plunge-the-light-can-at-any-time-go-from-green-to-red">consistency is your power</a>."
Orman also flagged a few silver linings: bond yields are collapsing, potentially boosting portfolios. The 10-year Treasury is sitting at 3.8%, helping on the mortgage front. <a href="https://www.benzinga.com/government/regulations/25/04/44601482/gold-holds-above-3100-mark-price-surge-reflects-growing-economic-uncertainty-here-are-some-etfs-to-capitalize-on-the-golden-rush">Gold has soared</a> past $3,150. And for those looking for stability, she pointed to a high-yield CD as a safer option for idle cash.
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
She also suggested now may be the right time to slowly begin Roth conversions. And on the commodities side, she noted that WTI crude oil has dropped below $65—a level that could signal a slide toward $45 if the trend holds.
As for stocks? She says stay diversified, avoid bottom-fishing, and lean into dividend-paying companies that have shown strength. "This is when dividend-paying stocks can really help stabilize your portfolio," she said, pointing to names like AT&amp;T and Verizon.
Orman's message wasn't alarmist—it was direct. Stay calm. Stick to the plan. And whatever you do, don't invest money you'll need anytime soon.
"Let's take this one day at a time, together," she wrote. "Be kind to yourself. Be kind to others. And always remember—you are stronger than your fear."
Read Next:
<ul>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
<li><a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a></li>
</ul>

Personal Finance

Suze Orman Says 'When Sentiment Is This Fearful, It's Not the Time to Sell' — But If You'll Need the Money in 5 Years, It Shouldn't Be in the Market

Guggenheim analyst Jason Cassorla initiates coverage on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Buy rating and announces Price Target of $326.

Initiation

Guggenheim Initiates Coverage On Humana with Buy Rating, Announces Price Target of $326

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Donegal Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGICA#NASDAQ">DGICA</a>) with a Outperform and raises the price target from $16 to $17.

DGICA

Keefe, Bruyette & Woods Maintains Outperform on Donegal Gr, Raises Price Target to $17

Jefferies analyst Stephanie Moore maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and lowers the price target from $560 to $455.

SAIA

Jefferies Maintains Buy on Saia, Lowers Price Target to $455

WIIM

Walmart shares are trading higher after the company reaffirmed its expectation for Q1 sales growth of approximately 3% to 4%, despite ongoing economic uncertainty. The retailer also emphasized its ability to maintain flexibility to invest in pricing as tariffs are implemented.

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains American Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFG#NYSE">AFG</a>) with a Market Perform and lowers the price target from $144 to $126.

Keefe, Bruyette & Woods Maintains Market Perform on American Financial Group, Lowers Price Target to $126

Guggenheim analyst Jason Cassorla initiates coverage on Ardent Health Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARDT#NYSE">ARDT</a>) with a Buy rating and announces Price Target of $16.

ARDT

Guggenheim Initiates Coverage On Ardent Health Partners with Buy Rating, Announces Price Target of $16

<a href="https://www.bloomberg.com/news/articles/2025-04-09/amazon-cancels-some-inventory-orders-from-china-after-tariffs" title="https://www.bloomberg.com/news/articles/2025-04-09/amazon-cancels-some-inventory-orders-from-china-after-tariffs">https://www.bloomberg.com/news/articles/2025-04-09/amazon-cancels-some-inventory-orders-from-china-after-tariffs</a>

AMZN

'Amazon Cancels Some Inventory Orders From China After Tariffs' - Bloomberg News

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) with a Outperform and lowers the price target from $286 to $274.

Keefe, Bruyette & Woods Maintains Outperform on Travelers Companies, Lowers Price Target to $274

Jefferies analyst Stephanie Moore maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Buy and lowers the price target from $170 to $135.

Jefferies Maintains Buy on XPO, Lowers Price Target to $135

Guggenheim analyst Subbu Nambi maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and lowers the price target from $45 to $37.

VCYT

Guggenheim Maintains Buy on Veracyte, Lowers Price Target to $37

CRWD

CrowdStrike Holdings shares are trading higher after the company announced an expansion of its partnership with Alphabet's Google Cloud to enable end-to-end security for AI innovation.

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Skyward Specialty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKWD#NASDAQ">SKWD</a>) with a Outperform and lowers the price target from $62 to $57.

SKWD

Keefe, Bruyette & Woods Maintains Outperform on Skyward Specialty, Lowers Price Target to $57

Jefferies analyst Stephanie Moore maintains Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a Hold and lowers the price target from $195 to $165.

ODFL

Jefferies Maintains Hold on Old Dominion Freight Line, Lowers Price Target to $165

Earnings

Press Releases

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Presentations at Upcoming Medical Meetings

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Comments

CalciMedica

Notizie

Ultime notizie per CalciMedica (NASDAQ:CALC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO